Join Eupraxia Pharmaceuticals for a virtual KOL event featuring Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) who will join company management to discuss the unmet medical need and current treatment landscape for eosinophilic esophagitis (EoE).

The event will focus on data from the Phase 1b/2a RESOLVE clinical trial and highlight clinical development plans evaluating EP-104GI for the treatment of EoE. Utilizing the company’s proprietary DiffuSphere™ technology, EP-104GI has shown the potential to target drug delivery to the esophageal tissue and improve treatment outcomes for the EoE patient population.

A live question and answer session will follow the formal presentation.